Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RYTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -9.152M
March 31, 2026 -44.18M
December 31, 2025 -25.39M
September 30, 2025 -26.62M
June 30, 2025 -23.31M
March 31, 2025 -40.35M
December 31, 2024 -18.84M
September 30, 2024 -25.22M
June 30, 2024 -29.08M
March 31, 2024 -40.74M
December 31, 2023 -29.38M
September 30, 2023 -29.25M
June 30, 2023 -41.09M
March 31, 2023 -36.43M
December 31, 2022 -34.00M
September 30, 2022 -46.99M
June 30, 2022 -38.81M
March 31, 2022 -53.63M
December 31, 2021 -40.47M
September 30, 2021 -40.16M
June 30, 2021 -31.84M
March 31, 2021 -33.53M
Date Value
December 31, 2020 -29.12M
September 30, 2020 -27.03M
June 30, 2020 -29.73M
March 31, 2020 -36.10M
December 31, 2019 -32.22M
September 30, 2019 -33.60M
June 30, 2019 -25.55M
March 31, 2019 -31.38M
December 31, 2018 -20.98M
September 30, 2018 -16.94M
June 30, 2018 -12.48M
March 31, 2018 -11.65M
December 31, 2017 -7.885M
September 30, 2017 -8.417M
June 30, 2017 -6.142M
March 31, 2017 -7.016M
December 31, 2016
September 30, 2016 -4.443M
June 30, 2016 -6.21M
March 31, 2016 -6.387M
December 31, 2015 -3.436M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
BioMarin Pharmaceutical, Inc. 168.11M
Cytokinetics, Inc. -159.84M
Exelixis, Inc. 307.74M